These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20686242)

  • 1. High performance liquid chromatography using UV detection for the simultaneous quantification of the new non-nucleoside reverse transcriptase inhibitor etravirine (TMC-125), and 4 protease inhibitors in human plasma.
    Hirano A; Takahashi M; Kinoshita E; Shibata M; Nomura T; Yokomaku Y; Hamaguchi M; Sugiura W
    Biol Pharm Bull; 2010; 33(8):1426-9. PubMed ID: 20686242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients.
    D'Avolio A; Baietto L; Siccardi M; Sciandra M; Simiele M; Oddone V; Bonora S; Di Perri G
    Ther Drug Monit; 2008 Dec; 30(6):662-9. PubMed ID: 18824956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantification of darunavir and etravirine in human peripheral blood mononuclear cells using high performance liquid chromatography tandem mass spectrometry (LC-MS/MS), clinical application in a cohort of 110 HIV-1 infected patients and evidence of a potential drug-drug interaction.
    Belkhir L; De Laveleye M; Vandercam B; Zech F; Delongie KA; Capron A; Yombi J; Vincent A; Elens L; Haufroid V
    Clin Biochem; 2016 May; 49(7-8):580-6. PubMed ID: 26742721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples.
    Quaranta S; Woloch C; Paccou A; Giocanti M; Solas C; Lacarelle B
    Ther Drug Monit; 2009 Dec; 31(6):695-702. PubMed ID: 19865000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conventional HPLC method used for simultaneous determination of the seven HIV protease inhibitors and nonnucleoside reverse transcription inhibitor efavirenz in human plasma.
    Takahashi M; Yoshida M; Oki T; Okumura N; Suzuki T; Kaneda T
    Biol Pharm Bull; 2005 Jul; 28(7):1286-90. PubMed ID: 15997115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation.
    D'Avolio A; Simiele M; Siccardi M; Baietto L; Sciandra M; Oddone V; Stefani FR; Agati S; Cusato J; Bonora S; Di Perri G
    J Pharm Biomed Anal; 2011 Mar; 54(4):779-88. PubMed ID: 21071165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous quantification of lopinavir and ritonavir in human plasma by high performance liquid chromatography coupled with UV detection.
    Kou H; Ye M; Fu Q; Han Y; Du X; Xie J; Zhu Z; Li T
    Sci China Life Sci; 2012 Apr; 55(4):321-7. PubMed ID: 22566088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine.
    Kakuda TN; Schöller-Gyüre M; Hoetelmans RM
    Antivir Ther; 2010; 15(6):817-29. PubMed ID: 20834094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application.
    Keil K; Hochreitter J; DiFrancesco R; Zingman BS; Reichman RC; Fischl MA; Gripshover B; Morse GD
    Ther Drug Monit; 2007 Feb; 29(1):103-9. PubMed ID: 17304157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous determination of six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir), the active metabolite of nelfinavir (M8) and non-nucleoside reverse transcriptase inhibitor (efavirenz) in human plasma by high-performance liquid chromatography.
    Hirabayashi Y; Tsuchiya K; Kimura S; Oka S
    Biomed Chromatogr; 2006 Jan; 20(1):28-36. PubMed ID: 15971289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The validation of plasma darunavir concentrations determined by the HPLC method for protease inhibitors.
    Takahashi M; Kudaka Y; Okumura N; Hirano A; Banno K; Kaneda T
    Biol Pharm Bull; 2007 Oct; 30(10):1947-9. PubMed ID: 17917268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography.
    Notari S; Bocedi A; Ippolito G; Narciso P; Pucillo LP; Tossini G; Donnorso RP; Gasparrini F; Ascenzi P
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb; 831(1-2):258-66. PubMed ID: 16406832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).
    Arribas JR
    Curr Opin HIV AIDS; 2009 Nov; 4(6):507-12. PubMed ID: 20048718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma.
    Weller DR; Brundage RC; Balfour HH; Vezina HE
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Apr; 848(2):369-73. PubMed ID: 17081812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
    De Meyer S; Lathouwers E; Dierynck I; De Paepe E; Van Baelen B; Vangeneugden T; Spinosa-Guzman S; Lefebvre E; Picchio G; de Béthune MP
    AIDS; 2009 Sep; 23(14):1829-40. PubMed ID: 19474650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction.
    Colombo S; Guignard N; Marzolini C; Telenti A; Biollaz J; Decosterd LA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Oct; 810(1):25-34. PubMed ID: 15358304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma.
    Titier K; Lagrange F; Péhourcq F; Edno-Mcheik L; Moore N; Molimard M
    Ther Drug Monit; 2002 Jun; 24(3):417-24. PubMed ID: 12021635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.
    Ribera E; Azuaje C; Lopez RM; Diaz M; Feijoo M; Pou L; Crespo M; Curran A; Ocaña I; Pahissa A
    AIDS; 2006 May; 20(8):1131-9. PubMed ID: 16691064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
    Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Rightmire A; Sankoh S; Wilber R
    AIDS; 2005 Apr; 19(7):685-94. PubMed ID: 15821394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.
    Schiller DS; Youssef-Bessler M
    Clin Ther; 2009 Apr; 31(4):692-704. PubMed ID: 19446143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.